Accent Group has reported a slowdown in sales growth for the 2025 financial year, with sales increasing by just 1.5 per cent to $1.5 billion. The ASX-listed retailer, valued at $1 billion, operates over 900 stores across various chains, including Hype DC, The Athlete’s Foot, Platypus, Stylerunner and Nude Lucy. Accent Group specialises in the […]
Accent Group Sales Growth Slows Read More »
Latitude Group has reported a substantial increase in first-half profit, driven by higher lending and increased spending volumes. The company announced a dividend payout as receivables reached a five-year high. Statutory net profit after tax surged to $39.7 million for the six months ending June 30, representing a 341 per cent increase compared to the
Latitude Group Profits Surge in First Half Read More »
WAM Leaders Limited (ASX: WLE), a listed investment company managed by Wilson Asset Management, has announced an increased fully franked full year dividend of 9.4 cents per share. The final dividend will be 4.7 cents per share, fully franked. This represents a fully franked dividend yield of 7.1% and a grossed-up dividend yield of 10.1%,
WAM Leaders (WLE) Boosts Fully Franked Full Year Dividend Read More »
Microequities Asset Management Group Limited (ASX:MAM), an Australian investment management firm specialising in listed industrial small and microcap companies, has released its FY25 financial results, showcasing significant growth in key metrics. The company reported a 19% increase in Net Profit After Tax (NPAT) to $7.1 million and a 39% increase in operating profit to $10.4
Microequities (ASX:MAM) Announces Strong FY25 Results, Anticipates Continued Growth Read More »
Microequities Asset Management Group Limited (MAM), an ASX-listed company managing investment funds, has announced a 19.3% increase in profit from ordinary activities after tax, attributable to owners, reaching $7,149,776 for the year ended 30 June 2025. This compares to $5,990,697 in the previous corresponding period. Revenue from ordinary activities also saw a rise of 9.3%,
Microequities (MAM) Reports 19.3% Profit Increase, Declares Final Dividend Read More »
Falcon Metals Limited (ASX:FAL), a mineral exploration company focused on high-grade goldfields in Victoria, Australia, has announced a successful placement to raise A$20.0 million before costs. The placement, priced at A$0.57 per share, was led by high-quality institutions including North American, European, and Australian funds. Applications for the placement significantly exceeded the funds sought, demonstrating
Siren Gold Limited (ASX: SNG), a New Zealand-focused gold exploration and development company, has announced it has secured firm commitments to raise $4 million through a placement to new and existing sophisticated and institutional investors. The company’s flagship asset, the Sams Creek Gold Project, hosts a JORC Mineral Resource Estimate (MRE) of 824,000 ounces of
Siren Gold (ASX: SNG) Announces $4 Million Capital Raise Read More »
Lakes Blue Energy (LKO) has released an update on drilling operations at its Wombat-5, side-track-1 (ST-1) well in the Gippsland Basin, Victoria. Lakes Blue Energy is an ASX-listed company focused on developing gas resources. The announcement details progress as of 8:00 am AEST today, indicating that the well has been operating for 15 days since
Lakes Blue Energy Provides Drilling Update for Wombat-5 Well Read More »
WAM Global Limited (WGB), a listed investment company providing investors with exposure to an actively managed diversified portfolio of high quality undervalued international growth companies and exposure to market mispricing opportunities, has announced its preliminary final report for the year ended 30 June 2025. The report showcases a substantial increase in revenue and profit compared
WAM Global (WGB) Reports Strong FY25 Results, Boosts Final Dividend Read More »
Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001. NUZ-001 is the company’s lead investigational therapy
FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response Read More »
